Russell Thomas
Member
BOD
AXXAM
Italy
Biography
Russell Thomas was appointed Director of Strategic Alliances at Axxam in October 2017; prior to that he held the role of Director of Discovery Research. Before joining Axxam in 2015, he was General Manager of Siena Biotech, having previously held the positions of Head of Medicinal Chemistry and then as Director of Portfolio Operations and Alliances. Between September 2012 and November 2013 he was VP of Lead Discovery at Proteros in Munich Germany. He assisted in the startup of Rodin Therapeutics, co-founded by Proteros and Atlas Ventures. Between 1998 and 2004 he was Department Head at Evotec in Oxford, UK. He worked at Glaxo, subsequently Glaxo Wellcome between 1991 and 1998 with positions of increasing responsibility in Medicinal Chemistry. In his scientific career Russell Thomas has worked on a range of projects delivering clinical and preclinical candidates, including selisistat, currently in Phase II clinical trials for Huntington's disease. Originally from Swansea, Wales, he graduated in chemistry from the University of Kent at Canterbury, followed by a Ph.D with Prof. Stan Roberts at Exeter University, UK. Russell Thomas was appointed Director of Strategic Alliances at Axxam in October 2017; prior to that he held the role of Director of Discovery Research. Before joining Axxam in 2015, he was General Manager of Siena Biotech, having previously held the positions of Head of Medicinal Chemistry and then as Director of Portfolio Operations and Alliances. Between September 2012 and November 2013 he was VP of Lead Discovery at Proteros in Munich Germany. He assisted in the startup of Rodin Therapeutics, co-founded by Proteros and Atlas Ventures. Between 1998 and 2004 he was Department Head at Evotec in Oxford, UK. He worked at Glaxo, subsequently Glaxo Wellcome between 1991 and 1998 with positions of increasing responsibility in Medicinal Chemistry. In his scientific career Russell Thomas has worked on a range of projects delivering clinical and preclinical candidates, including selisistat, currently in Phase II clinical trials for Huntington's disease. Originally from Swansea, Wales, he graduated in chemistry from the University of Kent at Canterbury, followed by a Ph.D with Prof. Stan Roberts at Exeter University, UK.
Research Interest
Biotechnology, Molecular Biology and Biochemistry
